zacks.com · 30 jun

Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.

seekingalpha.com · 25 jun

Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity

Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins.

zacks.com · 24 jun

Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.

zacks.com · 23 jun

Boston Scientific (BSX) Gains As Market Dips: What You Should Know

The latest trading day saw Boston Scientific (BSX) settling at $45.6, representing a +2.86% change from its previous close.

zacks.com · 23 jun

Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

zacks.com · 17 jun

Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note

Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.

fool.com · 13 jun

Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months

Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Sell-side analysts remain relatively upbeat on the stock.

seekingalpha.com · 12 jun

Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific has experienced a ~53% collapse over twelve months, driven by guidance cuts, WATCHMAN deceleration, EP share loss, and a mixed CHAMPION-AF readout. FY26 guidance was cut to 6.5-8.0% organic growth and $3.34-$3.41 EPS, with management tempering long-term 10%+ growth expectations. BSX trades at a significant discount to peers (12.6x FY27E P/E), despite maintaining a robust ~8% revenue and ~10-11% EPS growth profile.